Is Eton Pharmaceuticals, Inc. (ETON) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.6% / 30% | 3.3% / 30% | 1.2% / 30% | 0.0% / 5% | ✓ HALAL |
| DJIM | 6.6% / 33% | 3.3% / 33% | 1.2% / 33% | 0.0% / 5% | ✓ HALAL |
| MSCI | 39.3% / 33% | 19.6% / 33% | 7.0% / 33% | 0.0% / 5% | ✗ NOT HALAL |
| S&P | 6.6% / 33% | 3.3% / 33% | 1.2% / 33% | 0.0% / 5% | ✓ HALAL |
| FTSE | 39.3% / 33% | 19.6% / 33% | 7.0% / 50% | 0.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 59.8% | |
| Operating Margin | 21.0% | |
| Net Margin | -5.8% | |
| Return on Equity (ROE) | -18.2% | |
| Return on Assets (ROA) | 3.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $969,000 |
| Free Cash Flow | -$9M |
| Total Debt | $30M |
| Debt-to-Equity | 118.8 |
| Current Ratio | 1.6 |
| Total Assets | $76M |
Price & Trading
| Last Close | $23.45 |
| 50-Day MA | $17.49 |
| 200-Day MA | $16.95 |
| Avg Volume | 278K |
| Beta | 1.2 |
|
52-Week Range
$11.09
| |
About Eton Pharmaceuticals, Inc. (ETON)
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Eton Pharmaceuticals, Inc. (ETON) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Eton Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Eton Pharmaceuticals, Inc.'s debt ratio?
Eton Pharmaceuticals, Inc.'s debt ratio is 6.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 39.3%.
What are Eton Pharmaceuticals, Inc.'s key financial metrics?
Eton Pharmaceuticals, Inc. has a market capitalization of $634M, and revenue of $39M. The company maintains a gross margin of 59.8% and a net margin of -5.8%. Return on equity stands at -18.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.